Publications by authors named "Bi Feng"

Claim this Profile
C
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).
Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Xiufeng Liu, Feng Bi, Zhifeng Wu, Feng Shen

Liver Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated multi-omics analysis revealed that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth via the Hippo/YAP signaling axis.
Tingting Huang, Meng Tang, Qiulin Tang, Ye Di, Jiayu Wang, Feng Bi

Int J Surg· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.
Muhammad Masroor Hussain, Bi Feng, Ju-Mei Wang, Ao-Qiang Zhai, Fu-Yu Li

Cancer Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer.
Jie Hu, Qilong Liu, Bi Feng, Yanling Lu, Kai Chen

Cancer Res Treat· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.
Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Jufeng Wang

Eur J Med Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.
Gongmin Zhu, Lijiao Pei, Di Ye, Qiulin Tang, Huanji Xu, Feng Bi

Biochim Biophys Acta Rev Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.
Bi Feng, Siqi Yang, Zhiqiang He, Yushi Dai, Ruiqi Zou

Oncol Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1/CTLA-4 bispecific): a case report and literature review.
Chenge Zhang, Miao Dai, Jun Yang, Wenfang Tian, Si Huang, Feng Bi

Gynecol Oncol Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.
Sheng Zhou, Hongwei Xia, Huanji Xu, Qiulin Tang, Yongzhan Nie, Feng Bi

J Exp Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.
Wenke Li, Menghui Xu, Mo Cheng, Jing Wei, Lin Zhu, Feng Bi

Cancer Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of advanced NUTc of the nasal cavity: case report and review of the literature.
Ningping Xiao, Cheng Lin, Tingjie Yu, Feng Bi, Pingping Tan

Discov Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI-based radiomic nomogram for predicting disease-free survival in patients with locally advanced rectal cancer.
Jun Liu, Ke Liu, Fang Cao, Pingsheng Hu, Feng Bi

Abdom Radiol (NY)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial.
Jing Wei, Pengfei Zhang, Qiancheng Hu, Xiaolong Cheng, Chaoyong Shen, Hongfeng Gou, Feng Bi

Front Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of catalytic destruction of dichloromethane and ethyl acetate mixture over HPO-RuO/CeO catalyst.
Jiawen Chen, Qingjie Meng, Feng Bi, Jingkun Chen, Xiaole Weng

J Environ Sci (China)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering triple O-Ti-O vacancy associates for efficient water-activation catalysis.
Feng Bi, Qingjie Meng, Yili Zhang, Hao Chen, Boqiong Jiang, Hanfeng Lu

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma.
Chen Huang, Chenliang Zhang, Jiajin Li, Yichun Duan, Qiulin Tang, Feng Bi

Cell Biol Toxicol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.
George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Feng Bi, Feng Shen

Hepatol Int· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Pot Synthesis of (CrMnFeCoNi)O High-Entropy Oxides for Efficient Catalytic Oxidation of Propane: A Promising Substitute for Noble Metal Catalysts.
Yang Li, Bowen Han, Feng Bi, Zhongbiao Wu, Xiaole Weng

ACS Appl Mater Interfaces· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
Feng Bi, Jian Dong, Chuan Jin, Zuoxing Niu, Wenhui Yang, Wenlei Feng

J Hematol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction.
Chenliang Zhang, Huanji Xu, Qiulin Tang, Yichun Duan, Hongwei Xia, Feng Bi

EMBO Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy.
Di Ye, Shuang Zhou, Xinyu Dai, Huanji Xu, Qiulin Tang, Feng Bi

Biochim Biophys Acta Rev Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT-based radiomics for differentiating peripherally located pulmonary sclerosing pneumocytoma from carcinoid.
Yi Zhang, Xiaohuang Yang, Feng Bi, Lu Wen, Yue Niu

Med Phys· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study.
Yichun Duan, Jielang Li, Shuang Zhou, Feng Bi

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting RAF dimers in RAS mutant tumors: From biology to clinic.
Huanhuan Yin, Qiulin Tang, Hongwei Xia, Feng Bi

Acta Pharm Sin B· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and advantage of immunotherapy for melanoma intramuscular co-expression of plasmid-encoded PD-1 and CTLA-4 scFvs.
Yueyao Yang, Qian Huang, Mo Cheng, Lu Deng, Xun Liu, Xiufeng Zheng, Feng Bi

Am J Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis